Alivus Life Sciences Limited (BOM:543322)

Market Cap	117.58B
Revenue (ttm)	24.00B
Net Income (ttm)	4.96B
Shares Out	n/a
EPS (ttm)	40.32
PE Ratio	23.72
Forward PE	22.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,583
Average Volume	5,028
Open	935.65
Previous Close	931.75
Day's Range	920.90 - 943.40
52-Week Range	827.10 - 1,335.00
Beta	n/a
RSI	40.60
Earnings Date	Jul 23, 2025

About Alivus Life Sciences

Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company’s APIs are used in various therapeutic segments, in...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2011
• Employees: 2,014
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543322

Financial Performance

In 2024, Alivus Life Sciences's revenue was 23.87 billion, an increase of 4.54% compared to the previous year's 22.83 billion. Earnings were 4.86 billion, an increase of 3.13%.